AU2021220981A1 - Methods for treating tauopathy - Google Patents

Methods for treating tauopathy Download PDF

Info

Publication number
AU2021220981A1
AU2021220981A1 AU2021220981A AU2021220981A AU2021220981A1 AU 2021220981 A1 AU2021220981 A1 AU 2021220981A1 AU 2021220981 A AU2021220981 A AU 2021220981A AU 2021220981 A AU2021220981 A AU 2021220981A AU 2021220981 A1 AU2021220981 A1 AU 2021220981A1
Authority
AU
Australia
Prior art keywords
deuterated
optionally substituted
ester
acid
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021220981A
Other languages
English (en)
Inventor
Mikhail Sergeevich Shchepinov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biojiva LLC
Original Assignee
Biojiva LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biojiva LLC filed Critical Biojiva LLC
Publication of AU2021220981A1 publication Critical patent/AU2021220981A1/en
Assigned to RTMFP ENTERPRISES INC. reassignment RTMFP ENTERPRISES INC. Request for Assignment Assignors: RETROTOPE, INC.
Assigned to BIOJIVA LLC reassignment BIOJIVA LLC Amend patent request/document other than specification (104) Assignors: RTMFP ENTERPRISES INC.
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021220981A 2020-02-14 2021-02-12 Methods for treating tauopathy Pending AU2021220981A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062976958P 2020-02-14 2020-02-14
US62/976,958 2020-02-14
PCT/US2021/017981 WO2021163580A1 (en) 2020-02-14 2021-02-12 Methods for treating tauopathy

Publications (1)

Publication Number Publication Date
AU2021220981A1 true AU2021220981A1 (en) 2022-09-22

Family

ID=77273602

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021220981A Pending AU2021220981A1 (en) 2020-02-14 2021-02-12 Methods for treating tauopathy

Country Status (9)

Country Link
US (2) US20210251933A1 (https=)
EP (1) EP4103169A4 (https=)
JP (2) JP2023513901A (https=)
KR (1) KR20220140808A (https=)
CN (1) CN116507325A (https=)
AU (1) AU2021220981A1 (https=)
CA (1) CA3171330A1 (https=)
IL (1) IL295512A (https=)
WO (1) WO2021163580A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11510889B2 (en) 2021-02-05 2022-11-29 Retrotope, Inc. Methods for inhibiting the progression of neurodegenerative diseases
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
WO2022170134A2 (en) * 2021-02-05 2022-08-11 Retrotope, Inc. Dosing protocols for administering deuterated arachidonic acid or a prodrug thereof
US11491130B2 (en) * 2021-02-05 2022-11-08 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
KR20240055796A (ko) * 2021-09-03 2024-04-29 바이오지바 엘엘씨 중수소화 pufa를 이용한 세포 기능장애 및 세포 사멸의 억제를 위한 방법, 시스템 및 조성물
IL313592A (en) * 2021-12-21 2024-08-01 Biojiva Llc Methods and preparations for the treatment of inflammatory disease
WO2023192406A2 (en) * 2022-03-30 2023-10-05 Retrotope, Inc. Prophylactic methods for treating als

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10052299B2 (en) * 2009-10-30 2018-08-21 Retrotope, Inc. Alleviating oxidative stress disorders with PUFA derivatives
JP6106157B2 (ja) * 2011-04-26 2017-03-29 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． 神経変性障害および筋疾患に関与するｐｕｆａ
WO2012148930A2 (en) * 2011-04-26 2012-11-01 Retrotope, Inc. Oxidative retinal diseases
CN110167546A (zh) * 2016-11-17 2019-08-23 乐巢拓普有限公司 同位素修饰的组分及其治疗用途
EP3461479B1 (en) * 2017-09-27 2021-06-16 Julie Blivet Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions
JP2021527648A (ja) * 2018-06-15 2021-10-14 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 後細胞シグナル伝達因子の調節による免疫活性の低減

Also Published As

Publication number Publication date
WO2021163580A1 (en) 2021-08-19
US20250177339A1 (en) 2025-06-05
CN116507325A (zh) 2023-07-28
US20210251933A1 (en) 2021-08-19
JP2023513901A (ja) 2023-04-04
CA3171330A1 (en) 2021-08-19
JP2026035680A (ja) 2026-03-04
EP4103169A1 (en) 2022-12-21
IL295512A (en) 2022-10-01
KR20220140808A (ko) 2022-10-18
EP4103169A4 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
US20250177339A1 (en) Methods for Treating Tauopathy
Besouw et al. Cysteamine: an old drug with new potential
US20230165877A1 (en) Administration and dosage of diaminophenothiazines
US20250215026A1 (en) Deuterated Compounds, Compositions and Uses
EP2442647B1 (en) Dithiol compounds, derivatives, and uses therefor
ES2812800T3 (es) Nuevos usos terapéuticos de derivados de la bencilidenguanidina para el tratamiento de proteopatías
US12251373B2 (en) Compounds and methods of treating retinal degeneration
US11564924B2 (en) Pharmaceutical composition formed by combining pyridoxamine compound and thiamine compound
JP7296472B2 (ja) プリドピジンを使用したミトコンドリア関連疾患および障害（それらの症状を含む）の治療
WO2008060332A2 (en) Methods for treating or reducing muscle fatigue
ES2973215T3 (es) Agente terapéutico para la esclerosis lateral amiotrófica y composición para el tratamiento
WO2023023397A1 (en) Methods for inhibiting the progression of neurodegenerative diseases
ES2959243T3 (es) Nuevo tratamiento de enfermedades mitocondriales
GB2548839A (en) New uses and methods
JP2006516629A (ja) 置換キノリンおよび置換ジフェニルスルホンを含有する組成物および方法
ES2989515T3 (es) Fármaco profiláctico o terapéutico para enfermedades neurodegenerativas
JP7598195B2 (ja) 肥満及び関連する障害の予防及び治療のための化合物
WO2018170410A1 (en) Derivatives of sulindac can protect normal cells against oxidative damage
WO2016130908A1 (en) Therapeutic polysaccharide midi-gagr and related materials and methods
US20230241016A1 (en) Methods for inhibiting the progression of neurodegenerative diseases
HK40106579B (en) Administration and dosage of diaminophenothiazines
Tan et al. Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders
HK40023979B (en) Novel treatment of mitochondrial diseases
HK40023979A (en) Novel treatment of mitochondrial diseases

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: RTMFP ENTERPRISES INC.

Free format text: FORMER APPLICANT(S): RETROTOPE, INC.

HB Alteration of name in register

Owner name: BIOJIVA LLC

Free format text: FORMER NAME(S): RTMFP ENTERPRISES INC.